On March 24, 2025, IceCure Medical Ltd. announced that interim results from its ICESECRET study of cryoablation for patients with small renal masses (SRM) were presented at the European Association of Urology Conference in Madrid, Spain, which took place from March 21-24, 2025. The data confirmed that ProSense® cryoablation is highly effective for kidney tumors up to 3 cm and a safe procedure for kidney tumors up to 5 cm in people ineligible for surgery.
The study reported an 88.7% recurrence-free rate, demonstrating the strong efficacy of ProSense® in this indication. These positive interim results provide further clinical validation for IceCure's technology in addressing unmet needs in kidney cancer treatment. The presentation at a prominent European conference increases awareness and potential adoption among urologists.
This clinical evidence supports the expansion of ProSense®'s market potential beyond breast cancer, showcasing its versatility across various oncological applications. The findings are crucial for driving commercial traction and establishing cryoablation as a viable minimally invasive option for kidney tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.